Logo
x

Search

Subscribe Now

Novaliq

Novaliq’s Vevizye (Ciclosporin) gains the CHMP’s Positive Opinion to Prevent Moderate to Severe Dry Eye Disease (DED)

Novaliq’s Vevizye (Ciclosporin) gains the CHMP’s Positive Opinion to Prevent Moderate to Severe Dry Eye Disease (DED)

  • July 29, 2024
Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

  • August 24, 2023
PharmaShots' Key Highlights of Second Quarter 2022

PharmaShots' Key Highlights of Second Quarter 2022

  • June 30, 2022
Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

  • April 27, 2022
Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

  • December 22, 2021
Bausch + Lomb and Novaliq Report the NDA Submission of NOV03 (perfluorohexyloctane) to the US FDA for Dry Eye Disease Associated with Meibomian Gland Dysfunction

    Bausch + Lomb and Novaliq Report the NDA Submission of NOV03 (perfluorohexyloctane) to the US FDA for Dry Eye Disease Associated w...

    • July 8, 2022
    PharmaShots

      PharmaShots' Key Highlights of Second Quarter 2022

      • June 30, 2022
      PharmaShots Weekly Snapshots (April 25-29, 2022)

        PharmaShots Weekly Snapshots (April 25-29, 2022)

        • April 29, 2022
        Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

          Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

          • April 27, 2022
          PharmaShots Weekly Snapshots (December 20 - 23, 2021)

            PharmaShots Weekly Snapshots (December 20 - 23, 2021)

            • December 24, 2021
            Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

              Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

              • December 22, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.